<DOC>
	<DOCNO>NCT00203567</DOCNO>
	<brief_summary>To study efficacy safety bead extended-release Carbamazepine ( Equetro ) treatment patient Bipolar Disorder Major Depressive Episode .</brief_summary>
	<brief_title>Carbamazepine Extended-Release Treatment Bipolar Depression</brief_title>
	<detailed_description>Patients Bipolar I II Disorder Major Depressive Episode sign inform consent meet eligibility criterion begin treatment extended release carbamazepine ( ERC-CBZ ) . The dose ERC-CBZ initiate 200mg twice daily increase tolerated 200mg/day every 3 day 1200mg/day week 2 ( target dose ) . Then dose may increase investigator 's discretion , to1600mg/day tolerate week 8 , need great therapeutic response . Efficacy assess biweekly Montgomery-Asberg Depression Rating Scale ( MADRS ) Clinical Global Impression-Bipolar ( CGI-BP ) . Safety assess biweekly adverse event self-reports laboratory evaluation . ) .</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Carbamazepine</mesh_term>
	<criteria>Age 19 65 . Diagnosis Bipolar I II Disorder , currently experience major depressive episode without psychotic feature , confirm Mini International Neuropsychiatric Interview ( M.I.N.I. ) . Must experience least two previous mood episode past 10 year , least one hypomanic , full manic mixed episode . The current depressive episode must ≥ 2 week , ≤ 2 year duration . Must currently clinically significant depressive symptom define CGIS total score ≥ 4 . Must wash psychotropic medication ( except allow concomitant sedative insomnia ) bipolar illness least 3 day mood stabilizer 1 week antidepressant prior study drug initiation ( medication taper investigator 's discretion prior washout ) , continue meet entry criterion depressive symptom . Must willing discontinue psychotropic medication ( except allow concomitant sedative insomnia ) study period . No substance abuse/dependence previous 4 week ( except nicotine/caffeine ) Must give informed consent , and/or consent must obtain legally acceptable representative ( require IRB ) prior initiation protocol require procedure . Must able understand nature study , agree comply prescribed dosage regiment , report regularly schedule office visit communicate study personnel adverse event concomitant medication . Women childbearing potential ( WOCBP ) must use medically approve method birth control avoid pregnancy throughout study four week completion study manner risk pregnancy minimize . WOCBP must negative serum urine pregnancy test within 72 hour prior start study . Male female , race ethic origin Patients current diagnosis delirium , dementia , amnestic cognitive disorder ; schizophrenia ; borderline antisocial personality disorder ; mental disorder would interfere efficacy safety evaluation compliance . WOCBP unwilling unable use acceptable method avoid pregnancy entire study period four week completion study . Acceptable method include oral , injectable implanted contraceptive , intrauterine device barrier method condom , diaphragm , spermicide . Women pregnant breastfeeding , plan become pregnant study . Patients significant risk commit suicide homicide base history , mental status exam , investigator 's judgment . Patients receive psychotherapy ( individual , group , marriage , family therapy ) unless participation regular least 3 month prior randomization . Patients clinically significant thyroid pathology would interfere efficacy safety evaluation patient thyroid stimulate hormone ( TSH ) level &gt; 60 % upper limit normal . Patients undergoing treatment thyroid pathology ( e.g . thyroid supplementation ) stable least two month prior randomization . Patients history evidence medical condition would expose undue risk significant adverse event interfere assessment safety efficacy course trial , include limited hepatic , renal respiratory , cardiovascular , endocrine , neurologic , hematologic disease determine clinical judgment investigator . Patients history seizure ( except single childhood febrile seizure , posttraumatic , alcohol withdrawal ) history severe head trauma , stroke . Patients medication may serious drugdrug interaction ERCCBZ Clinically significant abnormal laboratory test result : Platelets &lt; 75,000/mm³ Hemoglobin &lt; 9g/dL Neutrophils , Absolute &lt; 1000/mm³ SGOT ( AST ) &gt; 3x Upper limit Normal SGPT ( ALT ) &gt; 3x Upper Limit Normal Creatinine &gt; 2mg/dL Diastolic blood pressure &gt; 105 mmHg TSH &gt; 60 % Upper Limit Normal Detectable level cocaine amphetamine urine drug screen . Other abnormal laboratory test vital sign result investigator 's judgment , medically significant , would impact safety patient interpretation result . Patients know allergic hypersensitivity carbamazepine ( alternative formulation ) . Patients fail adequate trial carbamazepine ( alternative formulation ) bipolar depression . Patients recent treatment longacting antipsychotic last dose less one full cycle plus one week Prisoners subject compulsorily detain ( involuntarily incarcerate ) treatment either psychiatric physical ( e.g . infectious disease ) illness study .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2008</verification_date>
	<keyword>bipolar depression</keyword>
	<keyword>carbamazepine ER</keyword>
	<keyword>Equetro</keyword>
</DOC>